Skip to main content

Studies Currently Enrolling

Interested in participating in one of our clinical trials? Complete this form to let us know.

See our flier with a list of research studies needing volunteers (Updated October 2020) and review the following:

Pediatrics

  • Constipation (ages 6-17) - A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, safety and efficacy study of linaclotide administered orally to children, Ages 6 to 17 years, with functional constipation (FC).
  • Depression (ages 7+) - A study for patients ages 7-17 years old with major depressive disorder. The purpose of this study is to examine the safety and efficacy of levomilnacipran (Fetzima) in children. Participants are randomized to one of three groups: placebo, levomilnacipran (Fetzima) or fluoxetine (Prozac). There is a $50 compensation per visit for time and travel. A parent or guardian is required to attend each of the nine visits.
  • Research database - You are being asked to participate in our research participant database. The purpose of this database is to collect personal health information to determine if you qualify for any current and/or future research studies.

Adults

  • COPD - A multi-center, randomized, 36-month, parallelgroup, non-inferiority, Phase 3 study to compare the effectiveness of 500 mcg QD oralternate regimen of roflumilast (Daliresp) therapy versus 250 mg QD, 500 mg QD three times per week, or alternate regimen of azithromycin therapy to prevent COPD exacerbations.
  • COVID-19 Vaccine - Phase 3 Efficacy Trial of a vaccine to prevent COVID-19 disease.
  • Depression - A 12-week study on adults with depression. Participants must be 18 to 80 years of age, have been diagnosed with major depressive disorder (MDD) for at least 12 weeks and have failed 2-5 trials of antidepressants or psychotherapy in the current major depressive episode. The study includes 8 office visits and pays $50 per visit.
  • Early Alzheimer's -  A 23-month study, with an optional extension phase study for an additional two years, for participants ages 50-90 years old with Alzheimer's or those with history of reported memory decline over the last year. This is a Phase 3 study that will test the effectiveness of a study drug, a monoclonal antibody, as a possible treatment. Compensation is provided for time and travel, and the study drug is provided free of charge.
  • Research database - You are being asked to participate in our research participant database. The purpose of this database is to collect personal health information to determine if you qualify for any current and/or future research studies.
  • Personality disorders - Genetic profile and ancestry information for participants 18 years and older, with personality disorders.
  • Schizophrenia - A Phase 2, randomized, double-blind, placebo-controlled study evaluating the safety, efficacy, and pharmacokinetics of miricorilant (CORT118335) in obese adult patients with schizophrenia and recent weight gain while taking antipsychotic medications.

Last modified: Oct 19, 2020
Contact Us

KU Wichita Center for Clinical Research

1010 N. Kansas
Wichita, KS 67214
Phone: 316-293-1833
Fax: 316-293-1829
Email: clinicaltrialunit@kumc.edu

Campus Map

Interested in joining a clinical trial?

Complete this form.

ID=x31954